{"component": "definition", "props": {"groups": [{"size": 13, "samples": [{"hash": "21uXQ6wSojJ", "uri": "/contracts/21uXQ6wSojJ#long-range-forecast", "label": "Commercial Manufacturing and Supply Agreement (Dynavax Technologies Corp)", "score": 29.1806983948, "published": true}, {"hash": "aFdCM5eONO", "uri": "/contracts/aFdCM5eONO#long-range-forecast", "label": "Commercial Supply Agreement (Amylin Pharmaceuticals Inc)", "score": 21.0, "published": true}, {"hash": "6iv1GG6ojUz", "uri": "/contracts/6iv1GG6ojUz#long-range-forecast", "label": "Commercial Supply Agreement (Idec Pharmaceuticals Corp / De)", "score": 21.0, "published": true}], "snippet_links": [{"key": "section-41", "type": "clause", "offset": [20, 31]}], "snippet": "shall be defined in Section 4.1.", "hash": "c8d9badf4af68e594a338e939a017fa4", "id": 1}, {"size": 7, "samples": [{"hash": "l56C2UjVrbA", "uri": "/contracts/l56C2UjVrbA#long-range-forecast", "label": "Exclusive License and Supply Agreement (Protalix BioTherapeutics, Inc.)", "score": 36.8658453114, "published": true}, {"hash": "5HDBWSrfAs9", "uri": "/contracts/5HDBWSrfAs9#long-range-forecast", "label": "Exclusive License and Supply Agreement (Protalix BioTherapeutics, Inc.)", "score": 26.9411354065, "published": true}, {"hash": "9NTXXVvP9BH", "uri": "/contracts/9NTXXVvP9BH#long-range-forecast", "label": "Exclusive License and Supply Agreement (Protalix BioTherapeutics, Inc.)", "score": 26.8535251617, "published": true}], "snippet_links": [], "snippet": "shall have the meaning assigned to it in Section 5.6(b).", "hash": "6527cd811d49dd2eef3995b2c0bb7a56", "id": 2}, {"size": 5, "samples": [{"hash": "lgBFs9p9vF9", "uri": "/contracts/lgBFs9p9vF9#long-range-forecast", "label": "Supply Agreement (Micron Technology Inc)", "score": 26.270362854, "published": true}, {"hash": "lv8JpUJ22YD", "uri": "/contracts/lv8JpUJ22YD#long-range-forecast", "label": "Supply Agreement (Micron Technology Inc)", "score": 24.2662563324, "published": true}], "snippet_links": [], "snippet": "shall have the meaning set forth in Section 3.15", "hash": "18e43ba69a5882ddc191ebe581c3a743", "id": 3}, {"size": 4, "samples": [{"hash": "4N24KjxV7HE", "uri": "/contracts/4N24KjxV7HE#long-range-forecast", "label": "Supply Agreement (Alliqua BioMedical, Inc.)", "score": 25.6078033447, "published": true}, {"hash": "aX5maje29N4", "uri": "/contracts/aX5maje29N4#long-range-forecast", "label": "Supply Agreement (Alliqua, Inc.)", "score": 25.2245044708, "published": true}, {"hash": "ehjFWqJZtwm", "uri": "/contracts/ehjFWqJZtwm#long-range-forecast", "label": "Supply Agreement (Celgene Corp /De/)", "score": 25.1779594421, "published": true}], "snippet_links": [], "snippet": "has the meaning set forth in Schedule 2.2, subsection (a)(i).", "hash": "59b1a3aa75cfaf1f25797ef9f1a9d64f", "id": 4}, {"size": 3, "samples": [{"hash": "ebs0C44umjA", "uri": "/contracts/ebs0C44umjA#long-range-forecast", "label": "Supply Agreement (Biomatrix Inc)", "score": 18.0, "published": true}, {"hash": "7meQgcjy7Wj", "uri": "/contracts/7meQgcjy7Wj#long-range-forecast", "label": "Supply Agreement (Biomatrix Inc)", "score": 18.0, "published": true}, {"hash": "7IbpV6q3u4", "uri": "/contracts/7IbpV6q3u4#long-range-forecast", "label": "Supply Agreement (Genzyme Corp)", "score": 18.0, "published": true}], "snippet_links": [{"key": "section-51", "type": "clause", "offset": [30, 41]}], "snippet": "means that term as defined in Section 5.1.", "hash": "c0564a98d2b5706bb763420189ed35f0", "id": 5}, {"size": 3, "samples": [{"hash": "6XAQQcZx7DZ", "uri": "/contracts/6XAQQcZx7DZ#long-range-forecast", "label": "Commercial Supply Agreement (Valneva SE)", "score": 35.2203979492, "published": true}], "snippet_links": [], "snippet": "has the meaning set forth in Section 2(4)(a).", "hash": "fe412c60408c74162bd49be83020b9b0", "id": 6}, {"size": 2, "samples": [{"hash": "hGHvFnwpFOw", "uri": "/contracts/hGHvFnwpFOw#long-range-forecast", "label": "Commercial Supply Agreement", "score": 30.3408622742, "published": true}, {"hash": "5rbxrugRXBJ", "uri": "/contracts/5rbxrugRXBJ#long-range-forecast", "label": "Commercial Supply Contract (Prothena Corp PLC)", "score": 28.1567420959, "published": true}], "snippet_links": [{"key": "section-33", "type": "clause", "offset": [39, 50]}], "snippet": "means the forecast levels set forth in Section 3.3.", "hash": "41d87a0b77d82c8be6ef4329350a7bf9", "id": 7}, {"size": 2, "samples": [{"hash": "7E49oIZzlDn", "uri": "/contracts/7E49oIZzlDn#long-range-forecast", "label": "License and Distribution Agreement (Pharmion Corp)", "score": 18.0, "published": true}], "snippet_links": [{"key": "set-out", "type": "definition", "offset": [16, 23]}, {"key": "section-92", "type": "clause", "offset": [27, 38]}], "snippet": "has the meaning set out in Section 9.2 herein.", "hash": "3a63ddf1c64d4877a65b4067ef35f5b4", "id": 8}, {"size": 1, "samples": [{"hash": "klIaMh4LSVB", "uri": "/contracts/klIaMh4LSVB#long-range-forecast", "label": "Combined Development and Commercial Supply Agreement (Omeros Corp)", "score": 36.244354248, "published": true}], "snippet_links": [{"key": "in-section-2", "type": "clause", "offset": [26, 38]}, {"key": "annex-4", "type": "definition", "offset": [42, 49]}], "snippet": "has the meaning set forth in Section 2 of Annex 4.", "hash": "c9a211920d83e401cac1b2171b690ffe", "id": 9}, {"size": 1, "samples": [{"hash": "2gSQpJORcEz", "uri": "/contracts/2gSQpJORcEz#long-range-forecast", "label": "Supply Agreement", "score": 20.3408622742, "published": false}], "snippet_links": [{"key": "section-51", "type": "clause", "offset": [30, 41]}, {"key": "manufacturing-costs", "type": "definition", "offset": [50, 69]}, {"key": "omitted-and-filed-separately-with-the-commission", "type": "clause", "offset": [121, 169]}, {"key": "minimum-price", "type": "clause", "offset": [191, 204]}, {"key": "section-41", "type": "clause", "offset": [241, 252]}, {"key": "net-revenues", "type": "definition", "offset": [264, 276]}, {"key": "specified-period", "type": "definition", "offset": [295, 311]}, {"key": "total-gross", "type": "definition", "offset": [316, 327]}, {"key": "invoice-price", "type": "definition", "offset": [328, 341]}, {"key": "sale-of-all-units", "type": "clause", "offset": [360, 377]}, {"key": "in-the-territory", "type": "clause", "offset": [406, 422]}, {"key": "retail-pharmacies", "type": "clause", "offset": [484, 501]}, {"key": "third-party-purchasers", "type": "clause", "offset": [522, 544]}, {"key": "books-and-records", "type": "clause", "offset": [590, 607]}, {"key": "in-accordance-with", "type": "clause", "offset": [647, 665]}, {"key": "generally-accepted-accounting-principles", "type": "clause", "offset": [666, 706]}, {"key": "consistently-applied", "type": "definition", "offset": [708, 728]}, {"key": "letters-patent", "type": "definition", "offset": [757, 771]}, {"key": "statutory-rights", "type": "clause", "offset": [783, 799]}, {"key": "relating-to", "type": "definition", "offset": [800, 811]}, {"key": "patent-applications", "type": "definition", "offset": [918, 937]}, {"key": "as-of-the-effective-date", "type": "clause", "offset": [956, 980]}, {"key": "patent-term-extensions-and-supplementary-protection-certificates", "type": "clause", "offset": [982, 1046]}, {"key": "each-case", "type": "definition", "offset": [1051, 1060]}, {"key": "exhibit-b", "type": "clause", "offset": [1077, 1086]}, {"key": "an-individual", "type": "clause", "offset": [1245, 1258]}, {"key": "a-corporation", "type": "clause", "offset": [1260, 1273]}, {"key": "agency-or-political-subdivision", "type": "definition", "offset": [1353, 1384]}, {"key": "formula-price", "type": "definition", "offset": [1410, 1423]}, {"key": "initial-product", "type": "clause", "offset": [1510, 1525]}, {"key": "following-groups", "type": "definition", "offset": [1651, 1667]}, {"key": "supply-forecast", "type": "clause", "offset": [1856, 1871]}, {"key": "section-52", "type": "clause", "offset": [1908, 1919]}, {"key": "supply-price", "type": "definition", "offset": [1932, 1944]}, {"key": "in-effect", "type": "definition", "offset": [1946, 1955]}, {"key": "at-any-time", "type": "clause", "offset": [1956, 1967]}, {"key": "price-per-unit", "type": "clause", "offset": [1990, 2004]}, {"key": "agreement-for", "type": "clause", "offset": [2070, 2083]}, {"key": "the-provisions-of-section", "type": "clause", "offset": [2155, 2180]}, {"key": "the-case", "type": "definition", "offset": [2192, 2200]}, {"key": "section-42", "type": "clause", "offset": [2209, 2220]}, {"key": "international-license-agreement", "type": "definition", "offset": [2362, 2393]}, {"key": "the-trademark", "type": "clause", "offset": [2429, 2442]}, {"key": "other-marks", "type": "definition", "offset": [2545, 2556]}, {"key": "service-marks", "type": "definition", "offset": [2572, 2585]}, {"key": "in-writing", "type": "definition", "offset": [2609, 2619]}, {"key": "from-time-to-time", "type": "clause", "offset": [2620, 2637]}, {"key": "the-parties-hereto", "type": "clause", "offset": [2641, 2659]}, {"key": "in-connection-with", "type": "clause", "offset": [2677, 2695]}, {"key": "the-promotion", "type": "definition", "offset": [2696, 2709]}, {"key": "sale-of-the-products", "type": "clause", "offset": [2725, 2745]}, {"key": "treatment-pack", "type": "definition", "offset": [2797, 2811]}, {"key": "quantity-of", "type": "clause", "offset": [2826, 2837]}, {"key": "treatment-course", "type": "definition", "offset": [2877, 2893]}, {"key": "with-respect-to", "type": "clause", "offset": [2950, 2965]}, {"key": "currency-of", "type": "definition", "offset": [3081, 3092]}, {"key": "the-united-states-of-america", "type": "clause", "offset": [3093, 3121]}], "snippet": "means that term as defined in Section 5.1. 1.13. \"Manufacturing Costs\" shall mean the * *Confidential portions have been omitted and filed separately with the Commission. -2- <Page> * 1.14. \"Minimum Price\" shall mean that term as defined in Section 4.1(b). 1.15. \"Net Revenues\" shall mean for a specified period the total gross invoice price received from the sale of all Units by Wyeth and its Affiliates in the Territory during such period to non-Affiliated wholesalers, hospitals, retail pharmacies, patients and other third party purchasers, * Such amounts shall be determined from the books and records of Wyeth and its Affiliates maintained in accordance with generally accepted accounting principles, consistently applied. 1.16. \"Patents\" shall mean Letters Patent or similar statutory rights relating to any Product (including any continuation-in-part, continuation or division thereof or substitute thereof), patent applications which are pending as of the Effective Date, patent term extensions and Supplementary Protection Certificates, in each case as set forth on Exhibit B hereto, together with any supplementary or complementary protection certificates therefor if and when such are granted. 1.17. \"Person\" or \"person\" shall mean an individual, a corporation, a partnership, a trust, an unincorporated organization or a government or any agency or political subdivision thereof. 1.18. \"Per Unit Formula Price\" shall mean that term as defined in Section 4.1(c). 1.19. \"Product(s)\" shall mean the Initial Product, together with any Improvements (as defined in Section 1.8) to the Initial Product. 1.20. \"Region\" shall mean any one of the following groups of countries * *Confidential portions have been omitted and filed separately with the Commission. -3- <Page> 1.21. \"Syringe\" shall mean a pre-package 2.0 ml syringe of the Product. 1.22. \"Supply Forecast\" shall mean that term as defined in Section 5.2. 1.23. The \"Supply Price\" in effect at any time shall mean the supply price per unit of a Product or Extended Products to be paid by Wyeth under this Agreement for resale in the Territory, as determined at such time in accordance with the provisions of Section 4.1 or, as the case may be, Section 4.2 hereof. 1.24. \"Territory\" shall mean, collectively, the Territory as defined in the US License Agreement and the Territory as defined in the International License Agreement. 1.25. \"Trademarks\" shall mean (i) the trademark Synvisc(R) and each other \u2587\u2587\u2587\u2587, trademark or service \u2587\u2587\u2587\u2587 described on Exhibit B hereto, and (ii) any other marks, trademarks or service marks, as may be agreed upon in writing from time to time by the parties hereto for use by Wyeth in connection with the promotion, marketing and sale of the Products and Extended Products under this Agreement. 1.26. \"Treatment Pack\" shall mean a quantity of the Initial Product sufficient for one treatment course, consisting of three Syringes. 1.27. \"Unit\" shall mean, with respect to the Initial Product, a 2.0 ml syringe of the Initial Product. 1.28. \"U.S. Dollars\" and \"US$\" shall mean the lawful currency of the United States of America.", "hash": "8e28709e936042e46bc97c9369554834", "id": 10}], "next_curs": "CmASWmoVc35sYXdpbnNpZGVyY29udHJhY3RzcjwLEhpEZWZpbml0aW9uU25pcHBldEdyb3VwX3Y1NiIcbG9uZy1yYW5nZS1mb3JlY2FzdCMwMDAwMDAwYQyiAQJlbhgAIAA=", "definition": {"title": "Long Range Forecast", "size": 45, "snippet": "shall be defined in Section 4.1.", "id": "long-range-forecast", "examples": ["Each <strong>Long Range Forecast</strong> shall be deemed to be revised by any subsequent Forecast.", "In the event Auxilium projects a shortfall in capacity based on the <strong>Long Range Forecast</strong>, the Parties will jointly discuss alternatives to increase such capacity, and the Parties shall promptly meet to discuss a reasonable manner of proceeding.", "Within * after the expiration of each Contract Quarter Wyeth shall provide to Biomatrix an updated * supply forecast (the &quot;Supply Forecast&quot;) and the * shall be consistent with the firm purchase orders previously delivered pursuant to Section 7, provided that commencing in * after the U.S. Launch Date Biomatrix&#x27;s obligation to supply Products under the Supply Forecasts shall not increase * The Supply Forecast shall supersede the <strong>Long Range Forecast</strong> for any applicable period.", "In the event Protalix anticipates that it will be unable to supply the quantities of Drug Substance reflected in a <strong>Long Range Forecast</strong>, Protalix shall promptly notify Pfizer and the Supply Chain Committee shall work to remedy the shortfall in accordance with and subject to the terms of this Section 5 in an effort to assure that the necessary capacity exists.", "Unless otherwise agreed to by the parties during the Term, the <strong>Long Range Forecast</strong> shall be updated by Pfizer annually by July 1 of each calendar year during the Term.", "The Applicable Capacity may be adjusted, from time to time upon either Party\u2019s written request, based on the <strong>Long Range Forecast</strong>.", "Unless otherwise agreed to by the Parties during the Term, the <strong>Long Range Forecast</strong> shall be updated by Pfizer and reviewed with Auxilium on an annual basis.", "For the avoidance of doubt, and without limiting any of the foregoing, \u2587\u2587\u2587\u2587\u2587\u2587\u2587\u2587\u2587\u2587 is not obligated to reserve resources as long as the <strong>Long Range Forecast</strong> is not a Binding Forecast.", "The initial <strong>Long Range Forecast</strong> shall be included in the Product Addendum (pursuant to Exhibit D) and shall be considered the \u201cInitial <strong>Long Range Forecast</strong>\u201d.", "The annual forecast for the first full year of the <strong>Long Range Forecast</strong> shall be the \u201cAnnual Forecast\u201d."], "related": [["rolling-forecast", "Rolling Forecast", "Rolling Forecast"], ["forecast", "Forecast", "Forecast"], ["forecast-gdp", "Forecast GDP", "Forecast GDP"], ["cash-flow-forecast", "Cash Flow Forecast", "Cash Flow Forecast"], ["pjm-region-peak-load-forecast", "PJM Region Peak Load Forecast", "PJM Region Peak Load Forecast"]], "related_snippets": [], "updated": "2025-11-15T04:39:58+00:00"}, "json": true, "cursor": ""}}